UK-based biopharmaceutical company AstraZeneca has announced a $3.5bn investment to expand its research and manufacturing ...

AstraZeneca Plc is increasingly looking to the US for growth as its once fast-expanding China business faces challenges amid ...

Cambridge, England-based biopharmaceutical giant AstraZeneca is pouring billions of dollars into properties in the United ...

Upon Pfizer’s closure of the Ann Arbor research site, he joined the infection group at AstraZeneca, in Waltham, MA, where his focus was again on anti-infective discovery and development over a 5-year ...

AstraZeneca has extended its cardiorenal pipeline ... Marc de Garidel, chief executive of Waltham, Massachusetts-based CinCor, said the takeover "offers the prospect of accelerating the ...

The executive in charge of AstraZeneca operations in China is under detention by Chinese authorities who are investigating employees there, the company said. The disclosure comes after AstraZeneca ...

Over the past three years, additional insurance fraud cases have emerged involving AstraZeneca employees in various Chinese regions. The investigation focuses on potential breaches of data privacy ...

Officials say the 104-mile trail will eventually connect Boston to Northampton. As of now, 60 miles of the project are fully ...

Steven Goldstein is based in London and responsible for MarketWatch's coverage of financial markets in Europe, with a particular focus on global macro and commodities. Previously, he was ...

Q3 revenue and core EPS beat estimates AstraZeneca announces $3.5 billion US investment CEO says growth looks set to continue through 2025 Shares down as market focuses on co's China issues ...

AstraZeneca Plc said its experimental obesity pill was well tolerated by patients with type-2 diabetes as it presented data from several studies testing its three new weight-loss medicines. The ...